Phase I evaluation of telatinib, a VEGF receptor tyrosine kinase inhibitor, in combination with bevacizumab in subjects with advanced solid tumors
Titel:
Phase I evaluation of telatinib, a VEGF receptor tyrosine kinase inhibitor, in combination with bevacizumab in subjects with advanced solid tumors
Auteur:
Langenberg, M.H.G. Witteveen, P.O. Roodhart, J. Lolkema, M.P. Verheul, H.M.W. Mergui-Roelvink, M. Brendel, E. Krätzschmar, J. Loembé, B. Nol-Boekel, A. Christensen, O. Schellens, J.H.M. Voest, E.E.